CAR T-cell Therapy Yields Durable Remissions in FL.

Source :: Cancer discovery [Cancer Discov] 2019 Sep; Vol. 9 (9), pp. OF4. Date of Electronic Publication: 2019 Jul 22.
Publication Year :: 2019
Abstract: In a phase I/II study, chimeric antigen receptor T cells produced complete remissions in 88% of patients with refractory or relapsed follicular lymphoma, all of whom remained in remission after a median of 2 years of follow-up. The treatment induced cytokine release syndrome and neurotoxicity in 50% of patients, but none developed side effects more severe than grade 2.<br /> (©2019 American Association for Cancer Research.)